HC Wainwright Has Optimistic Outlook of ACHV Q2 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Investment analysts at HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for Achieve Life Sciences in a research note issued to investors on Tuesday, May 12th. HC Wainwright analyst B. Folkes now forecasts that the biopharmaceutical company will post earnings per share of ($0.18) for the quarter, up from their prior estimate of ($0.33). HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($0.82) EPS, FY2029 earnings at $1.00 EPS and FY2030 earnings at $1.51 EPS.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.11.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group set a $13.00 price objective on Achieve Life Sciences and gave the stock a “buy” rating in a report on Monday, April 20th. Weiss Ratings cut Achieve Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th. Finally, Wall Street Zen upgraded Achieve Life Sciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $14.67.

Achieve Life Sciences Stock Performance

Achieve Life Sciences stock opened at $5.96 on Thursday. The stock has a 50-day simple moving average of $4.03 and a 200 day simple moving average of $4.46. The company has a quick ratio of 4.39, a current ratio of 4.39 and a debt-to-equity ratio of 0.52. Achieve Life Sciences has a 12-month low of $2.00 and a 12-month high of $6.15. The stock has a market capitalization of $317.25 million, a price-to-earnings ratio of -5.32 and a beta of 2.25.

Institutional Investors Weigh In On Achieve Life Sciences

A number of large investors have recently added to or reduced their stakes in ACHV. AQR Capital Management LLC bought a new stake in Achieve Life Sciences in the 1st quarter valued at $32,000. Qube Research & Technologies Ltd bought a new stake in Achieve Life Sciences in the 2nd quarter valued at $232,000. Raymond James Financial Inc. raised its stake in Achieve Life Sciences by 57.1% in the 2nd quarter. Raymond James Financial Inc. now owns 295,058 shares of the biopharmaceutical company’s stock valued at $667,000 after acquiring an additional 107,218 shares during the period. Jane Street Group LLC acquired a new position in Achieve Life Sciences in the 2nd quarter valued at $159,000. Finally, Bank of America Corp DE grew its holdings in Achieve Life Sciences by 39.9% in the 2nd quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 9,617 shares in the last quarter. Institutional investors own 33.52% of the company’s stock.

More Achieve Life Sciences News

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Achieve Life Sciences and a $12 price target, while raising near-term EPS estimates for Q2, Q3, and Q4 2026, signaling improved expectations around the company’s path toward commercialization. Analyst estimate updates for ACHV
• Positive Sentiment: Achieve Life Sciences announced several senior leadership appointments, including a new board member and commercial leaders, which should strengthen preparations for a potential product launch of cytisinicline. Leadership appointments release
• Positive Sentiment: The company reported Q1 EPS of -$0.19, beating the consensus estimate of -$0.30, which suggests tighter expense control or better-than-expected operating performance. Earnings press release
• Neutral Sentiment: HC Wainwright raised some longer-term estimates, but also cut FY2028, FY2029, and FY2030 EPS assumptions, showing that the outlook remains uncertain even as near-term expectations improve. Analyst estimate revisions for ACHV
• Negative Sentiment: Investor concern remains centered on regulatory risk, since cytisinicline is still awaiting an FDA decision with a PDUFA date of June 20, 2026, and approval is not guaranteed. Regulatory risk article

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.